Online inquiry

IVTScrip™ mRNA-Anti-CD274, MPDL3280A(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12237MR)

This product GTTS-WQ12237MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CD274 gene. The antibody can be applied in Solid tumors, Renal cell carcinoma (RCC) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001267706.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 29126
UniProt ID Q9NZQ7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD274, MPDL3280A(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ12237MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1308MR IVTScrip™ mRNA-Anti-MET, ABT-700(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ABT-700
GTTS-WQ8349MR IVTScrip™ mRNA-Anti-MUC1, hPAM4(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA hPAM4
GTTS-WQ14737MR IVTScrip™ mRNA-Anti-CD19, SGN-19A(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA SGN-19A
GTTS-WQ2924MR IVTScrip™ mRNA-Anti-ERBB3, AMG888(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AMG888
GTTS-WQ4253MR IVTScrip™ mRNA-Anti-Factor VIII substitute, BIIB031(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA BIIB031
GTTS-WQ11763MR IVTScrip™ mRNA-Anti-CTLA4, MK-1308(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MK-1308
GTTS-WQ9178MR IVTScrip™ mRNA-Anti-CD37, IMGN-529(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA IMGN-529
GTTS-WQ1181MR IVTScrip™ mRNA-Anti-TNF, ABP 501(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ABP 501
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW